Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Non-Randomized, Open-Label, Multi-Center Phase 1/2 Study Evaluating the Safety, Pharmacokinetics and Efficacy of ABT-414 in Japanese Subjects With Malignant Glioma

NCT02590263 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT02590263
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02590263 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Non-Randomized, Open-Label, Multi-Center Phase 1/2 Study Evaluating the Safety, Pharmacokinetics and Efficacy of ABT-414 in Japanese Subjects With Malignant Glioma
Lead sponsor
AbbVie
Phase
Phase 1/2
Overall status
Completed
Start date
August 24, 2015
Completion date
August 27, 2020
Enrollment
53 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma multiforme, malignant glioma